SCHEMBL4334938

SCHEMBL4334938

O=C(NCc1ccc(OCC(F)(F)F)nc1)C1c2ccccc2C(=O)N1C1CN(C(=O)O)C1

nearest known ligand 0.62

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 17/20 0.62
KCNH2 Q12809 12/20 0.62
SCN5A Q14524 12/20 0.55
SMN1; SMN2 Q16637 1/20 0.51
FPR1 P21462 2/20 0.50
CYP1A2 P05177 1/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13579104 0.90 SCN9A (0.70) SCN9AKCNH2SCN5ASMN1; SMN2FPR1
SCHEMBL4326647 0.89 SCN9A (0.64) SCN9AKCNH2SCN5ASMN1; SMN2FPR1
SCHEMBL4457879 0.87 SCN9A (0.68) SCN9AKCNH2SCN5ASMN1; SMN2FPR1
SCHEMBL13579101 0.86 SCN9A (0.69) SCN9AKCNH2SCN5ASMN1; SMN2FPR1
SCHEMBL4323000 0.81 SCN9A (0.80) SCN9AKCNH2SCN5A
SCHEMBL4334944 0.80 SCN9A (0.43) SCN9AKCNH2SCN5A
SCHEMBL13579023 0.78 SCN9A (0.67) SCN9AKCNH2SCN5ASMN1; SMN2FPR1
SCHEMBL4329573 0.77 SCN9A (0.66) SCN9AKCNH2SCN5ASMN1; SMN2FPR1
SCHEMBL4457611 0.76 SCN9A (1.00) SCN9AKCNH2SCN5A
SCHEMBL3896305 0.75 SCN9A (0.71) SCN9AKCNH2SCN5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009145720-A1 ISOINDOLINE DERIVATIVES COMPRISING ADDITIONAL HETEROCYCLIC GROUPS AND THEIR USE IN THE TREATMENT OF PAIN DISORDERS ASTRAZENECA AB (SE) 2009-12-03 WO claimed
WO-2009145720-A1 ISOINDOLINE DERIVATIVES COMPRISING ADDITIONAL HETEROCYCLIC GROUPS AND THEIR USE IN THE TREATMENT OF PAIN DISORDERS ASTRAZENECA AB (SE) 2009-12-03 WO disclosed